ALKERMES PLC (ALKS) Fundamental Analysis & Valuation

NASDAQ:ALKS • IE00B56GVS15

29.28 USD
+0.08 (+0.27%)
At close: Mar 4, 2026
29.38 USD
+0.1 (+0.34%)
After Hours: 3/4/2026, 8:08:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ALKS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 520 industry peers in the Biotechnology industry. ALKS gets an excellent profitability rating and is at the same time showing great financial health properties. ALKS is not valued too expensively and it also shows a decent growth rate. These ratings would make ALKS suitable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. ALKS Profitability Analysis

1.1 Basic Checks

  • ALKS had positive earnings in the past year.
  • ALKS had a positive operating cash flow in the past year.
  • In multiple years ALKS reported negative net income over the last 5 years.
  • In the past 5 years ALKS always reported a positive cash flow from operatings.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • ALKS has a better Return On Assets (9.72%) than 93.65% of its industry peers.
  • ALKS has a better Return On Equity (13.28%) than 94.04% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 10.90%, ALKS belongs to the top of the industry, outperforming 94.42% of the companies in the same industry.
  • ALKS had an Average Return On Invested Capital over the past 3 years of 18.21%. This is in line with the industry average of 19.05%.
  • The last Return On Invested Capital (10.90%) for ALKS is well below the 3 year average (18.21%), which needs to be investigated, but indicates that ALKS had better years and this may not be a problem.
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROIC 10.9%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • ALKS's Profit Margin of 16.37% is amongst the best of the industry. ALKS outperforms 92.31% of its industry peers.
  • ALKS has a Operating Margin of 17.21%. This is amongst the best in the industry. ALKS outperforms 93.27% of its industry peers.
  • Looking at the Gross Margin, with a value of 86.69%, ALKS belongs to the top of the industry, outperforming 88.85% of the companies in the same industry.
  • ALKS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ALKS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ALKS is creating value.
  • The number of shares outstanding for ALKS has been increased compared to 1 year ago.
  • Compared to 5 years ago, ALKS has more shares outstanding
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 5.56 indicates that ALKS is not in any danger for bankruptcy at the moment.
  • ALKS has a better Altman-Z score (5.56) than 73.65% of its industry peers.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.56
ROIC/WACC1.42
WACC7.7%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • ALKS has a Current Ratio of 3.55. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ALKS (3.55) is comparable to the rest of the industry.
  • ALKS has a Quick Ratio of 3.19. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.19, ALKS is doing worse than 60.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.19
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALKS Growth Analysis

3.1 Past

  • ALKS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.76%.
  • The Earnings Per Share has been growing by 31.92% on average over the past years. This is a very strong growth
  • Looking at the last year, ALKS shows a decrease in Revenue. The Revenue has decreased by -5.25% in the last year.
  • ALKS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.28% yearly.
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%

3.2 Future

  • ALKS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.80% yearly.
  • The Revenue is expected to grow by 11.16% on average over the next years. This is quite good.
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. ALKS Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.02, ALKS is valued on the expensive side.
  • Based on the Price/Earnings ratio, ALKS is valued cheaply inside the industry as 94.62% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.03. ALKS is valued slightly cheaper when compared to this.
  • ALKS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 17.02
Fwd PE N/A
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaply inside the industry as 94.81% of the companies are valued more expensively.
  • ALKS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALKS is cheaper than 97.69% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.16
EV/EBITDA 14.51
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • ALKS has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as ALKS's earnings are expected to decrease with -2.65% in the coming years.
PEG (NY)N/A
PEG (5Y)0.53
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALKS Dividend Analysis

5.1 Amount

  • No dividends for ALKS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALKS Fundamentals: All Metrics, Ratios and Statistics

ALKERMES PLC

NASDAQ:ALKS (3/4/2026, 8:08:11 PM)

After market: 29.38 +0.1 (+0.34%)

29.28

+0.08 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners105.82%
Inst Owner Change2.02%
Ins Owners1.48%
Ins Owner Change6.38%
Market Cap4.88B
Revenue(TTM)1.48B
Net Income(TTM)241.66M
Analysts81.67
Price Target44.69 (52.63%)
Short Float %10.94%
Short Ratio9.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.45%
Min EPS beat(2)-16.95%
Max EPS beat(2)59.84%
EPS beat(4)3
Avg EPS beat(4)31.82%
Min EPS beat(4)-16.95%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)15.4%
EPS beat(12)7
Avg EPS beat(12)24.7%
EPS beat(16)10
Avg EPS beat(16)139.34%
Revenue beat(2)1
Avg Revenue beat(2)3.48%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)8.51%
Revenue beat(4)2
Avg Revenue beat(4)4.47%
Min Revenue beat(4)-1.55%
Max Revenue beat(4)12.13%
Revenue beat(8)3
Avg Revenue beat(8)2.64%
Revenue beat(12)6
Avg Revenue beat(12)3.42%
Revenue beat(16)9
Avg Revenue beat(16)2.75%
PT rev (1m)0.29%
PT rev (3m)0.57%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-3.14%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 17.02
Fwd PE N/A
P/S 3.31
P/FCF 10.16
P/OCF 9.37
P/B 2.68
P/tB 2.81
EV/EBITDA 14.51
EPS(TTM)1.72
EY5.87%
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)2.88
FCFY9.84%
OCF(TTM)3.12
OCFY10.67%
SpS8.86
BVpS10.92
TBVpS10.41
PEG (NY)N/A
PEG (5Y)0.53
Graham Number20.55
Profitability
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROCE 13.07%
ROIC 10.9%
ROICexc 15.63%
ROICexgc 16.66%
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
FCFM 32.55%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ROICexc(3y)43.15%
ROICexc(5y)N/A
ROICexgc(3y)50.12%
ROICexgc(5y)N/A
ROCE(3y)21.84%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 148.79%
Cap/Sales 2.74%
Interest Coverage 250
Cash Conversion 185.24%
Profit Quality 198.76%
Current Ratio 3.55
Quick Ratio 3.19
Altman-Z 5.56
F-Score6
WACC7.7%
ROIC/WACC1.42
Cap/Depr(3y)110.09%
Cap/Depr(5y)83%
Cap/Sales(3y)2.59%
Cap/Sales(5y)2.72%
Profit Quality(3y)136.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%
EBIT growth 1Y-39.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.82%
EBIT Next 3Y26.72%
EBIT Next 5Y26.75%
FCF growth 1Y18.41%
FCF growth 3YN/A
FCF growth 5Y63.91%
OCF growth 1Y18.59%
OCF growth 3Y191.61%
OCF growth 5Y44.45%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 4 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -135.86% in the next year.